Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 10.08.20 with a price of €118.06. With a performance of -2.64%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 0.141% | 0.141% | 19.638% | 53.692% |
| iShares Core DAX® | 1.604% | -7.448% | 3.039% | 46.264% |
| iShares Nasdaq 100 | -0.734% | -1.864% | 15.425% | 72.335% |
| iShares Nikkei 225® | 1.296% | -6.795% | 34.306% | 52.282% |
| iShares S&P 500 | -0.394% | -2.336% | 9.907% | 55.100% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


